The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Open accessAbstract
BACKGROUND: Controversy persists regarding the extent of shared pathways between arterial and venous thrombosis and whether treatments of known efficacy for one disease process have consistent benefits for the other. Observational studies have yielded variable estimates of the effect of statin therapy on the risk of venous thromboembolism, and evidence from randomized trials is lacking. METHODS: We randomly assigned 17,802 apparently healthy men and women with both low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to receive rosuvastatin, 20 mg per day, or placebo. We followed participants for the first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data on an intention-to-treat basis. RESULTS: During a median follow-up period of 1.9 years (maximum, 5.0), symptomatic venous thromboembolism occurred in 94 participants: 34 in the rosuvastatin group and 60 in the placebo group. The rates of venous thromboembolism were 0.18 and 0.32 event per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio with rosuvastatin, 0.57; 95% confidence interval [CI], 0.37 to 0.86; P=0.007); the corresponding rates for unprovoked venous thromboembolism (i.e., occurring in the absence of a known malignant condition, trauma, hospitalization, or surgery) were 0.10 and 0.17 (hazard ratio, 0.61; 95% CI, 0.35 to 1.09; P=0.09) and for provoked venous thromboembolism (i.e., occurring in patients with cancer or during or shortly after trauma, hospitalization, or surgery), 0.08 and 0.16 (hazard ratio, 0.52; 95% CI, 0.28 to 0.96; P=0.03). The rates of pulmonary embolism were 0.09 in the rosuvastatin group and 0.12 in the placebo group (hazard ratio, 0.77; 95% CI, 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (hazard ratio, 0.45; 95% CI, 0.25 to 0.79; P=0.004). Consistent effects were observed in all the subgroups examined. No significant differences were seen between treatment groups in the rates of bleeding episodes. CONCLUSIONS: In this trial of apparently healthy persons, rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism. (ClinicalTrials.gov number, NCT00239681.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citationSilverstein, M. D., Heit, J. A., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.585 · Cited by 2,660
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,641
Self-citationCardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis
Ageno, W., Becattini, C., Brighton, T., Selby, R., & Kamphuisen, P. W. (2008) · Circulation · doi:10.1161/circulationaha.107.709204 · Cited by 974
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169405 · Cited by 801
Grady, D., Wenger, N. K., Herrington, D., Khan, S., Furberg, C., Hunninghake, D., Vittinghoff, E., Hulley, S., & for the Heart and Estrogen/progestin Replacement Study Research Group (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00002 · Cited by 715
Cited by
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationHeart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citationPleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247
Epidemiology of venous thromboembolism
Heit, J. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.83 · Cited by 1,277
New Fundamentals in Hemostasis
Versteeg, H. H., Heemskerk, J. W. M., Levi, M., & Reitsma, P. H. (2013) · Physiological Reviews · doi:10.1152/physrev.00016.2011 · Cited by 1,126
The epidemiology of venous thromboembolism
Heit, J. A., Spencer, F. A., & White, R. H. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1311-6 · Cited by 1,093
Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis
Ageno, W., Becattini, C., Brighton, T., Selby, R., & Kamphuisen, P. W. (2008) · Circulation · doi:10.1161/circulationaha.107.709204 · Cited by 974
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp440 · Cited by 839
Ruiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Self-citationInflammation in Atherosclerosis: Transition From Theory to Practice
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0706 · Cited by 799
Self-citationDavidovici, B. B., Sattar, N., Jörg, P. C., Puig, L., Emery, P., Barker, J. N., van de Kerkhof, P., Ståhle, M., Nestle, F. O., Girolomoni, G., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.103 · Cited by 711
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -
Zhou, Q., & Liao, J. K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0110 · Cited by 567
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Self-citationAnti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Self-citationUndas, A., & Ariëns, R. A. S. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.230631 · Cited by 526
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Risk factors for venous and arterial thrombosis.
Previtali, E., Bucciarelli, P., Passamonti, S. M., & Martinelli, I. (2011) · PubMed · doi:10.2450/2010.0066-10 · Cited by 447
New insights into the mechanisms of venous thrombosis
Mackman, N. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60229 · Cited by 436
Ridker, P. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.037 · Cited by 414
Self-citationRisk Factors for Venous Thromboembolism: Results From the Copenhagen City Heart Study
Holst, A. G., Jensen, G., & Prescott, E. (2010) · Circulation · doi:10.1161/circulationaha.109.921460 · Cited by 396
Wolberg, A. S., Rosendaal, F. R., Weitz, J. I., Jaffer, I. H., Agnelli, G., Baglin, T., & Mackman, N. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.6 · Cited by 369
Schreiber, K., Sciascia, S., de Groot, P. G., Devreese, K., Jacobsen, S., Ruiz-Irastorza, G., Salmon, J. E., Shoenfeld, Y., Shovman, O., & Hunt, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.103 · Cited by 359
Cardiovascular Risk Factors Associated With Venous Thromboembolism
Gregson, J., Kaptoge, S., Bolton, T., Pennells, L., Willeit, P., Burgess, S., Bell, S., Sweeting, M., Rimm, E. B., Kabrhel, C., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4537 · Cited by 357
Self-citationHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315
“Furthermore, rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism by 43% when participants were followed for the first occurrence of pulmonary embolism or deep vein thrombosis [69].”
BackgroundThe role of leukocytes in thrombosis
Swystun, L. L., & Liaw, P. C. (2016) · Blood · doi:10.1182/blood-2016-05-718114 · Cited by 300
Madhavan, M. V., Bikdeli, B., Gupta, A., Jimenez, D., Burton, J. R., Der Nigoghossian, C., Chuich, T., Nouri, S. N., Dreyfus, I., Driggin, E., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1713152 · Cited by 258
Ridker, P. M., Genest, J., Boekholdt, S. M., Libby, P., Gotto, A. M., Nordestgaard, B. G., Mora, S., MacFadyen, J. G., Glynn, R. J., & Kastelein, J. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60713-1 · Cited by 256
Self-citationGlynn, R. J., Koenig, W., Nordestgaard, B. G., Shepherd, J., & Ridker, P. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-8-201004200-00005 · Cited by 252
Self-citationA Randomized Study of How Physicians Interpret Research Funding Disclosures
Kesselheim, A. S., Robertson, C. T., Myers, J. A., Rose, S. L., Gillet, V., Ross, K. M., Glynn, R. J., Joffe, S., & Avorn, J. (2012) · New England Journal of Medicine · doi:10.1056/nejmsa1202397 · Cited by 183
Self-citationPrimary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?
Barbhaiya, M., & Erkan, D. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0149-3 · Cited by 69
Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials
D’Ugo, E., Libby, P., & De Caterina, R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0246 · Cited by 54
Self-citationStatin use and lower extremity amputation risk in nonelderly diabetic patients
Sohn, M.-W., Meadows, J. L., Oh, E. H., Budiman-Mak, E., Lee, T. A., Stone, N. J., & Pearce, W. B. (2013) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.06.069 · Cited by 52
Insight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research
Suissa, S. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10218 · Cited by 28
Antiphospholipid syndrome: an update for clinicians and scientists
Vreede, A. P., Bockenstedt, P. L., & Knight, J. S. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000410 · Cited by 22
Metadata
- Authors
- Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Ridker, P. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-30
- Volume
- 360
- Issue
- 18
- Pages
- 1851-1861
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1593008417
- Cited by
- 752
- References
- 36
- FWCI
- 61.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.